The Risk of Falsely Declaring Noninferiority of Novel Latent Tuberculosis Treatment in Large Trials

Am J Respir Crit Care Med. 2020 Mar 1;201(5):511-513. doi: 10.1164/rccm.201911-2258ED.

Authors

Ibrahim Abubakar¹, Frank G J Cobelens^{2

3}, Molebogeng X Rangaka^{1

4

5}

Affiliations

¹ UCL Institute for Global HealthLondon, United Kingdom.
² Department of Global Health.
³ Amsterdam Institute for Global Health and DevelopmentAmsterdam University Medical CentersAmsterdam, the Netherlands.
⁴ Institute of Infectious Disease and Molecular Medicineand.
⁵ School of Public HealthUniversity of Cape TownCape Town, South Africa.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Latent Tuberculosis*

Grants and funding

RP-PG-0217-20009/DH_/Department of Health/United Kingdom